Vimarsana
Biggest News Aggregation in the World

Growth Engine Update News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Growth Engine Update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Growth Engine Update Today - Breaking & Trending Today

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and R - Vimarsana News

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and R

Published: August 8, 2022

Second Quarter 2022 Results:-- Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) –-- Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin) net sales of $10.2 million ---- Ad...

Source: pharmiweb.com
Related Topics:
United StatesNikhil LalwaniLisam WilsonMeredithw CookOakrum PharmaExchange CommissionOakrum PharmaceuticalsDrug AdministrationSite Communications IncPharmaceuticals IncBusiness DevelopmentSecond QuarterRare DiseaseRepository Corticotrophin InjectionPer ShareGeneral CounselPurified Cortrophin GelUnited HealthcareLaunch UpdateGrowth Engine UpdateCortrophin GelNet RevenueNorth AmericanPrivate Securities Litigation Reform ActAnnual Report
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin Gel - Vimarsana News

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin Gel

Published: August 8, 2022

08.08.2022 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record ...

Source: wallstreet-online.de
Related Topics:
United StatesOakrum PharmaExchange CommissionDrug AdministrationPharmaceuticals IncBusiness DevelopmentLaunch UpdateUnited HealthcareGrowth Engine UpdateCortrophin GelNet RevenuePurified Cortrophin GelNorth AmericanPrivate Securities Litigation ReformAnnual ReportMonths Ended JuneBefore BenefitIncome TaxesConvertible Preferred StockLoss AvailableCommon ShareholdersDiluted Loss Per ShareMezzanine EquityStockholder EquityIncome Available